Amaryllis Nucleics is a pioneering biotechnology company dedicated to advancing genomic research by developing a novel and accessible RNA sequencing (RNA-Seq) platform. Their core mission is to simplify complex RNA-Seq workflows, reducing them from days to hours, thereby making powerful sequencing capabilities available to a broader range of laboratories, even those with only basic qPCR thermocyclers. By democratizing this technology, Amaryllis Nucleics aims to accelerate scientific discovery and enable deeper insights into biological processes and disease mechanisms.
Serves as the company's primary center for research and development of its RNA sequencing technology, as well as housing corporate strategy, business development, and administrative operations.
While specific architectural highlights are not publicly promoted, the facility is expected to feature essential biotech infrastructure, including advanced molecular biology laboratories, specialized areas for sequencing equipment, and collaborative workspaces conducive to scientific innovation.
The work culture at Amaryllis Nucleics is likely dynamic, innovative, and research-intensive, fostering collaboration among scientists and engineers. As a startup in the biotech sector, it would emphasize a fast-paced environment, scientific rigor, and a strong focus on achieving breakthroughs in RNA sequencing.
The Palo Alto headquarters provides Amaryllis Nucleics with critical access to a rich ecosystem of top-tier talent, leading research institutions, venture capital, and potential industry partners, all of which are vital for growth and innovation in the biotechnology field.
Amaryllis Nucleics is currently focused on research and development within the United States, with its primary operations based in Palo Alto, California. While its physical presence is centralized, the company's ambition is to make its RNA sequencing technology globally accessible to researchers and laboratories worldwide. Future global functions would likely involve establishing partnerships for distribution, sales, and support as their technology matures and enters commercialization.
2627 Hanover Street
Palo Alto
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Amaryllis Nucleics' leadership includes:
Amaryllis Nucleics has been backed by several prominent investors over the years, including:
Based on publicly available information, Amaryllis Nucleics has not announced any major executive new hires or departures in the last 12 months. The co-founding leadership team appears to remain in place, guiding the company's strategic direction and technological development.
Discover the tools Amaryllis Nucleics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Amaryllis Nucleics has not officially published its email format, a common pattern for technology and biotech companies is [first_initial][last]@[companydomain].com. For example, using this pattern, an email for a hypothetical Jane Doe would be jdoe@amaryllisnucleics.com.
[first_initial][last]@amaryllisnucleics.com
Format
kpandit@amaryllisnucleics.com
Example
75%
Success rate
Business Wire • February 8, 2024
Amaryllis Nucleics presented compelling data showcasing the performance and simplified workflow of its novel RNA sequencing (RNA-Seq) platform at the Advances in Genome Biology and Technology (AGBT) General Meeting. The presentation highlighted the platform's potential to make RNA-Seq more accessible....more
Business Wire • June 21, 2022
Amaryllis Nucleics announced the successful closing of its seed funding round. The financing was led by OMX Ventures, with participation from Big Pi Ventures and an undisclosed angel investor. The company, an alumnus of the Illumina Accelerator, will use the funds to advance the development and validation of its innovative RNA sequencing platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Amaryllis Nucleics, are just a search away.